BioXcel Therapeutics

Traded on the St. Petersburg Stock Exchange
BioXcel Therapeutics is an American clinical stage biopharmaceutical company, focuses on artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology. It was incorporated in 2017 and is headquartered in New Haven, Connecticut.
BioXcel Therapeutics stock price chart
vol.
change
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

BioXcel Therapeutics balance sheet

Report period2017 2018 2019 2020 2021 2022
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

BioXcel Therapeutics cash flows

Report period2017 2018 2019 2020 2021 2022
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

BioXcel Therapeutics multipliers

Report period2017 2018 2019 2020 2021 2022
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

BioXcel Therapeutics profitability

Report period2017 2018 2019 2020 2021 2022
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
BioXcel Therapeutics assets
BioXcel Therapeutics cash flows

BioXcel Therapeutics shares

TickerNameTypeNominal valueISINPrice
BTAI:USBioXcel TherapeuticsCommon share-US09075P1057$2.81
BioXcel Therapeutics news
11.05.2022
BioXcel Therapeutics' GAAP loss for 3 months of 2022 was $31.472 million, up 19.3% from $26.376 million in the previous year.
Source: {source} pictogram ir.bioxceltherapeutics.com
Pictogram next
10.03.2022
BioXcel Therapeutics' GAAP loss for 2021 was $106.931 million, up 30.1% from $82.169 million the previous year.
Source: {source} pictogram ir.bioxceltherapeutics.com
Pictogram next
11.11.2021
BioXcel Therapeutics' GAAP loss for 9M 2021 was $80.806 million, up 32.3% from $61.083 million in the prior year.
Source: {source} pictogram ir.bioxceltherapeutics.com
Pictogram next
10.08.2021
BioXcel Therapeutics' GAAP loss for 6M 2021 was $53.995 million, up 48.6% from $36.33 million in the previous year.
Source: {source} pictogram ir.bioxceltherapeutics.com
Pictogram next
All BioXcel Therapeutics news
General information
Company nameBioXcel Therapeutics
Tags#artificial intelligence, #pharmacy, #biotechnology
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology
Business address555 Long Wharf Drive 12th Floor New Haven, CT 06511 United States
Mailing address555 Long Wharf Drive 12th Floor New Haven, CT 06511 United States
Websiteir.bioxceltherapeutics.com
Information disclosurewww.sec.gov